Articles

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Record identifier

TN_cdi_hal_primary_oai_HAL_inserm_03349042v1

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_03349042v1

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Publication information

Publisher

England: Elsevier Ltd

More information

SCOPE AND CONTENTS

Contents

Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of pirtobrutinib (working name; formerly known as LOXO-305), a highly selective, reversible BTK inhibitor, in these patients.
Patients wi...

ALTERNATIVE TITLES

Full title

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_hal_primary_oai_HAL_inserm_03349042v1

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_03349042v1

OTHER IDENTIFIERS

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(21)00224-5

How to access this item

Online

1 item

How to access?

Login with a Library card